Delayed growth and BLI of Luciferase-transfected MOPC315.BM-cells.

<p>(A) Tumor take experiment with MOPC315.BM.Luc (2×10⁵ cells i.v.) (n = 13) was overlaid that of MOPC315.BM shown in Fig. 1B (also 2×10⁵ cells i.v.). The survival curves showing development of paraplegia are significantly different (p<0.0001). (B) Levels of M315 myeloma protein in sera of mice in (A). M315 was significantly different at day 10, 20 and 30 (p<0.002). N.D. = Not Detected. (C–E) All scales in photons/second/cm²/steradian. (C) Timeline of bioluminescent signals in a representative BALB/c mouse injected with 2.0×10⁵ MOPC315.BM.Luc i.v. (D) Examples of typical sites of affection. I: sternum, femurs, spleen. II, III: spine, femurs, spleen. IV: spine, femurs, spleen, shoulder. (E) Tumor growth of MOPC315.BM.Luc in four representative BALB/c mice pictured at day 28. (F) Luminescence emitted from typical sites of growth as a function of time (n = 13). MOPC315.BM.Luc mice (open boxes) are compared to non-injected control mice (filled boxes). *p<0.031 for femur and spine. **p<0.04 for all indicated sites. (G) Frequency of tumor growth in various sites on day 10, 21 and 31. *Signals from the shoulder region could not be attributed to particular bones. (H) Correlation of serum myeloma protein M315 measured on days 10, 21 and 32 and average luminescence [radiance (photons/second/cm²/steradian)] emitted in individual mice (r = 0.8929, p<0.001).